๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Kiel
Clinical trial register · Germany

Clinical Trials in Kiel, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Germany and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 5051 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:51 UTC
5051
Studies in scope
all four open statuses
2882
Recruiting now
open to new participants
988
Lead sponsors
across recruiting studies
Top sites
Berlin 115 Essen 57 Hamburg 56 Cologne 48 Dresden 48
Narrow the registerReset
Recruitment status
Phase
Site location
Berlin115 Essen57 Hamburg56 Cologne48 Dresden48
All 184 locations
Target enrolment
to

Trials with a site in Kiel

12 of 5051 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Germany
Start
Recruiting
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
NCT07764978Newly Diagnosed Multiple Myeloma
AstraZeneca
Phase 3
750
Berlin, Cologne, Dresden, Essen, Freiburg im Breisgau, Hamburg, Kiel, Leipzig
2026-06-26
Recruiting
Prospective, Non-interventional Single-arm Study With Tezepelumab to Investigate the Change in Clinical and Patient-reported Outcomes in Patients With CRSwNP in Real-world (PETRICHOR)
NCT07633158Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
AstraZeneca
Observational
200
Dortmund, Hamburg, Heilbronn, Jena, Kiel, Mรผnchen, Neuenhagen, Rosenheim
2026-06-10
Recruiting
A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.
NCT07215702Sepsis, Acute Kidney Injury
AstraZeneca
Phase 2
124
Aachen, Essen, Frankfurt, Greifswald, Heidelberg, Kiel, Leipzig, Mรผnster
2026-02-10
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Cologne, Homburg, Kiel, Mainz, Mรผnchen, Wรผrzburg
2025-01-30
Active, closed
A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus
NCT06015737Cutaneous Lupus Erythematosus
AstraZeneca
Phase 3
339
Berlin, Bochum, Dresden, Erlangen, Essen, Freiburg im Breisgau, Hanover, Kiel
2024-06-29
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
NCT06350097Non-small Cell Lung Cancer
AstraZeneca
Phase 3
582
Berlin, Cologne, Erfurt, Frankfurt, Gรถttingen, Immenhausen, Kiel, Mainz
2024-04-29
Active, closed
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations
NCT05687266NSCLC
AstraZeneca
Phase 3
1,350
Bad Berka, Berlin, Frankfurt A. Main, Gauting, Gรผtersloh, Hamburg, Kassel, Kiel
2022-12-29
Recruiting
Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen
NCT05624450Viral Lung Infection and Acute Respiratory Failure
AstraZeneca
Phase 3
3,527
Augsburg, Berlin, Cologne, Hamburg, Hanover, Kiel, Leverkusen, Marburg
2022-12-13
Active, closed
A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 Inhibition
NCT05061134Melanoma
AstraZeneca
Phase 2
194
Berlin, Buxtehude, Heidelberg, Heilbronn, Kiel, Mainz, Mรผnchen, Regensburg
2022-08-11
Active, closed
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
NCT05113251Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
AstraZeneca
Phase 3
927
Augsburg, Berlin, Erlangen, Hamburg, Heidelberg, Kiel, Leipzig, Mรถnchengladbach
2021-10-25
Active, closed
A Study of T-DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761Breast Cancer
AstraZeneca
Phase 3
506
Berlin, Dresden, Erlangen, Essen, Frankfurt, Hamburg, Hanover, Kiel
2021-06-22
Rows per page Showing 1–12 of 12
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a German investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 28 September 2026. https://priyalifescience.com/clinical-trials-germany/city/kiel

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Germany and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,051 studies in total at the last sync on 26 Sep 2026, 19:51 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 12 of those studies with a site in Kiel that also match the filters currently applied.

How many clinical trials are recruiting in Kiel?

6 of the 12 studies on this page are recruiting new participants as of the 26 Sep 2026, 19:51 UTC sync. A further 0 have not yet opened recruitment, 6 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kiel), 12 studies
PhaseStudiesRecruitingShare
Phase 38366.7%
Phase 22116.7%
Observational118.3%
Phase 1/2118.3%

Most active sponsors

Lead sponsors with the most studies (Kiel)
Lead sponsorStudiesRecruiting
AstraZeneca126
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.